Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase first identified in a chromosomal translocation associated with some anaplastic large cell lymphomas (ALCL), a subset of T-cell non ...

An isogenic cell line was created to model cancer patients with the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene and tested for its ...

As a university law lecturer, Nat is struggling to make ends meet. Her monthly salary of 33,000 baht is only a fraction of the cost of the super-expensive cancer drug she has been taking.In August ...

Alecensa weight gain is underreported in ALK+ NSCLC trials, highlighting the need for increased awareness and proactive ...

The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The treatment is for a deadly sub-type of lung cancer that is more common in younger people and non-smokers, who have a specific mutation of the anaplastic lymphoma kinase (ALK) gene. It is often ...

for treating non-small-cell lung cancer (NSCLC) in adults whose cancer: is resectable (tumours 4 cm or over, or node positive) and has no epidermal growth factor receptor (EGFR) mutations or ...